IDXX - IDEXX Laboratories, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Westbrook,
United States
Type: Equity
IDXX price evolution
IDXX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $401.59 | $397.43 | $453.93 | |
| Short term investments | ||||
| Net receivables | $587.07 | $533.61 | $578.24 | $457.44 |
| Inventory | $389.8 | $379.96 | $390.6 | $380.28 |
| Total current assets | $1433.74 | $1528.61 | $1501.97 | $1495.25 |
| Long term investments | ||||
| Property, plant & equipment | $838.8 | $827.7 | $828.61 | $702.18 |
| Goodwill & intangible assets | $518.83 | $524.02 | $450.46 | |
| Total noncurrent assets | $1886.26 | $1851.54 | $1764.67 | |
| Total investments | ||||
| Total assets | $3350.77 | $3414.87 | $3353.51 | $3259.93 |
| Current liabilities | ||||
| Accounts payable | $110.6 | $117.47 | $117.46 | $110.64 |
| Deferred revenue | $64.78 | $66.24 | $65.73 | |
| Short long term debt | $420.11 | $325 | $325 | |
| Total current liabilities | $1009.22 | $1116.7 | $956.9 | $951.55 |
| Long term debt | $524.76 | $627.71 | $620.78 | $622.88 |
| Total noncurrent liabilities | $717.91 | $827.71 | $823.85 | |
| Total debt | $1047.82 | $1049.65 | $1047.55 | |
| Total liabilities | $1732.71 | $1834.61 | $1784.61 | $1775.39 |
| Shareholders' equity | ||||
| Retained earnings | $5116.29 | $4883.45 | $4680.15 | $4444.57 |
| Other shareholder equity | -$75.97 | -$85.18 | -$80.4 | $1484.53 |
| Total shareholder equity | $1580.25 | $1568.91 | $1484.53 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $453.93 | $112.55 | $144.45 | $383.93 |
| Short term investments | ||||
| Net receivables | $457.44 | $400.62 | $368.35 | $331.43 |
| Inventory | $380.28 | $367.82 | $269.03 | $209.87 |
| Total current assets | $1495.25 | $1101.48 | $955.65 | $1062.74 |
| Long term investments | ||||
| Property, plant & equipment | $702.18 | $649.47 | $692.77 | $646.34 |
| Goodwill & intangible assets | $450.46 | $459.47 | $458.38 | $295.89 |
| Total noncurrent assets | $1764.67 | $1645.29 | $1481.55 | $1231.82 |
| Total investments | ||||
| Total assets | $3259.93 | $2746.76 | $2437.2 | $2294.56 |
| Current liabilities | ||||
| Accounts payable | $110.64 | $110.22 | $116.14 | $74.56 |
| Deferred revenue | $65.73 | $68.8 | $81.21 | $88.73 |
| Short long term debt | $325 | $653.98 | $148.5 | $49.99 |
| Total current liabilities | $951.55 | $1235.8 | $763.58 | $582.76 |
| Long term debt | $622.88 | $694.39 | $862.58 | $935.53 |
| Total noncurrent liabilities | $823.85 | $902.23 | $983.63 | $1079.01 |
| Total debt | $1047.55 | $1449.61 | $1011.08 | $985.52 |
| Total liabilities | $1775.39 | $2138.03 | $1747.21 | $1661.77 |
| Shareholders' equity | ||||
| Retained earnings | $4444.57 | $3599.53 | $2920.44 | $2175.59 |
| Other shareholder equity | $1484.53 | $608.74 | -$53.48 | -$53.62 |
| Total shareholder equity | $1484.53 | $608.74 | $689.99 | $632.09 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $975.54 | $1003.58 | $964.1 | $901.6 |
| Cost of revenue | $384.42 | $371.02 | ||
| Gross Profit | $596.04 | $619.16 | $593.07 | $526.17 |
| Operating activities | ||||
| Research & development | $55.45 | $52.63 | ||
| Selling, general & administrative | $299.91 | $241.48 | ||
| Total operating expenses | $292.15 | $355.36 | $294.11 | $280.86 |
| Operating income | $263.8 | $298.96 | ||
| Income from continuing operations | ||||
| EBIT | $267.15 | $303.39 | ||
| Income tax expense | $66.07 | $55.76 | $59.9 | $45.15 |
| Interest expense | -$4.98 | $8.1 | $7.91 | -$5.63 |
| Net income | ||||
| Net income | $232.84 | $203.3 | $235.58 | $194.52 |
| Income (for common shares) | $203.3 | $235.58 | ||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3660.95 | $3367.32 | $2706.66 | |
| Cost of revenue | $1362.99 | $1135.62 | ||
| Gross Profit | $2189.97 | $2004.34 | $1571.04 | |
| Operating activities | ||||
| Research & development | $254.82 | $141.25 | ||
| Selling, general & administrative | $850.75 | $735.27 | ||
| Total operating expenses | $1092.84 | $1105.57 | $876.52 | |
| Operating income | $898.76 | $694.52 | ||
| Income from continuing operations | ||||
| EBIT | $899.83 | $694.75 | ||
| Income tax expense | $216.13 | $180.88 | $79.85 | |
| Interest expense | -$35.95 | $39.86 | $33.13 | |
| Net income | ||||
| Net income | $845.04 | $679.09 | $581.78 | |
| Income (for common shares) | $679.09 | $581.78 | ||
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | $203.3 | $235.58 | ||
| Operating activities | ||||
| Depreciation | $32.19 | $29.9 | ||
| Business acquisitions & disposals | -$77 | |||
| Stock-based compensation | $15.72 | $14.4 | ||
| Total cash flows from operations | $248.31 | $198.59 | ||
| Investing activities | ||||
| Capital expenditures | -$33.3 | -$30.27 | ||
| Investments | $0.4 | $0.33 | ||
| Total cash flows from investing | -$167.22 | -$32.91 | -$106.94 | -$125.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$210.16 | -$133.88 | ||
| Net borrowings | ||||
| Total cash flows from financing | -$645.29 | -$210.24 | -$144.07 | -$442 |
| Effect of exchange rate | $0.24 | -$1.01 | -$4.07 | $2.13 |
| Change in cash and equivalents | -$145.3 | $4.16 | -$56.5 | $341.39 |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $679.09 | $744.85 | $581.78 | |
| Operating activities | ||||
| Depreciation | $111.9 | $104.6 | $96 | |
| Business acquisitions & disposals | -$11.51 | -$173.42 | -$2.42 | |
| Stock-based compensation | $49.77 | $37.76 | $30.95 | |
| Total cash flows from operations | $542.98 | $755.55 | $648.06 | |
| Investing activities | ||||
| Capital expenditures | -$158.84 | -$119.55 | -$106.96 | |
| Investments | -$25 | |||
| Total cash flows from investing | -$125.25 | -$195.35 | -$292.97 | -$109.38 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$783.96 | -$700.21 | -$131.49 | |
| Net borrowings | $430.06 | $20.85 | -$94.65 | |
| Total cash flows from financing | -$442 | -$370.94 | -$697.41 | -$248.42 |
| Effect of exchange rate | $2.13 | -$8.61 | -$4.64 | $3.33 |
| Change in cash and equivalents | $341.39 | -$31.91 | -$239.47 | $293.6 |
News
Fundamentals
| Market cap | $34.34B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 82.04M |
| Revenue | $3.84B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $866.24M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 39.64 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 8.93 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $10.56 |
|---|---|
| ROA | 25.90% |
| ROE | N/A |
| Debt/Equity | 1.20 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.42 |
| Quick ratio | 1.03 |